Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 36, 2023 - Issue 2
Submit an article Journal homepage
27
Views
0
CrossRef citations to date
0
Altmetric
Case Studies

Recurrent malignant ovarian adenocarcinoma with central nervous system metastasis successfully treated with paclitaxel, carboplatin, capecitabine, and gemcitabine

Soroush Shahrokha University of Houston College of Medicine/HCA Houston Healthcare – Kingwood, Houston, TexasORCID Iconhttps://orcid.org/0000-0003-3931-5395
, DO, MSORCID Icon,
Soraya Salmanianb Faculty of Medicine, Onco-Pathology Research Center, Iran University of Medical Sciences, Tehran, Iran
, MD &
Mohadese Shahinc Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IranCorrespondence[email protected]
, MD
Pages 234-236 | Received 07 Jul 2022, Accepted 18 Oct 2022, Published online: 08 Nov 2022

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708.
  • Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578.
  • Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203. doi:10.3322/caac.20113.
  • Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi:10.1016/S0140-6736(18)32552-2.
  • Gaitskell V, Hermon K, Beral C, et al; Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835–1842. doi:10.1016/S0140-6736(14)61687-1.
  • Wentzensen N, Poole EM, Trabert B, et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016;34(24):2888–2898. doi:10.1200/JCO.2016.66.8178.
  • Jervis S, Song H, Lee A, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J Med Genet. 2014;51(2):108–113. doi:10.1136/jmedgenet-2013-102015.
  • Schorge JO, Modesitt SC, Coleman RL, et al. SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119(1):7–17. doi:10.1016/j.ygyno.2010.06.003.
  • Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–192. doi:10.6004/jnccn.2022.0008.
  • Dodge JE, Covens AL, Lacchetti C, et al; Gynecology Cancer Disease Site Group. Management of a suspicious adnexal mass: a clinical practice guideline. Curr Oncol. 2012;19(4):e244–e257. doi:10.3747/co.19.980.
  • Sadowski EA, Rockall AG, Maturen KE, Robbins JB, Thomassin-Naggara I. Adnexal lesions: imaging strategies for ultrasound and MR imaging. Diagn Interv Imaging. 2019;100(10):635–646. doi:10.1016/j.diii.2018.06.003.
  • Anthoulakis C, Nikoloudis N. Pelvic MRI as the “gold standard” in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: a systematic review. Gynecol Oncol. 2014;132(3):661–668. doi:10.1016/j.ygyno.2013.10.022.
  • Schummer M, Drescher C, Forrest R, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125(1):65–69. doi:10.1016/j.ygyno.2011.11.050.
  • Cao H, You D, Lan Z, Ye H, Hou M, Xi M. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies. Expert Rev Mol Diagn. 2018;18(4):371–383. doi:10.1080/14737159.2018.1457436.
  • Teh BH, Yong SL, Sim WW, Lau KB, Suharjono HN. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy. Horm Mol Biol Clin Investig. 2018;35(1):0029. doi:10.1515/hmbci-2018-0029.
  • Hogdall EV, Christensen L, Kjaer SK, et al. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study. Pathology. 2008;40(5):487–492. doi:10.1080/00313020802197889.
  • Deng K, Yang C, Tan Q, et al. Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients. Gynecol Oncol. 2018;150(3):460–465. doi:10.1016/j.ygyno.2018.06.022.
  • Pectasides D, Aravantinos G, Fountzilas G, et al. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005;25(5):3553–3558.
  • Wohl A, Kimchi G, Korach J, et al. Brain metastases from ovarian carcinoma: an evaluation of prognostic factors and treatment. Neurol India. 2019;67(6):1431–1436. doi:10.4103/0028-3886.273627.
  • Kim TJ, Song S, Kim CK, et al. Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2007;17(6):1252–1257. doi:10.1111/j.1525-1438.2007.00941.x.
  • Sehouli J, Pietzner K, Harter P, et al. Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: Results of a German multicenter study. Ann Oncol. 2010;21(11):2201–2205. doi:10.1093/annonc/mdq229.
  • Stopa BM, Cuoco JA, Adhikari S, Grider DJ, Rogers CM, Marvin EA. Iatrogenic leptomeningeal carcinomatosis following craniotomy for resection of metastatic serous ovarian carcinoma: a systematic literature review and case report. Front Surg. 2022;9:850050. doi:10.3389/fsurg.2022.850050.
  • Shen J, Sun X, Zhou J. Insights into the role of mesothelin as a diagnostic and therapeutic target in ovarian carcinoma. Front Oncol. 2020;10:1263. doi:10.3389/fonc.2020.01263.
  • Barber EL, Zsiros E, Lurain JR, Rademaker A, Schink JC, Neubauer NL. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer. J Gynecol Oncol. 2013;24(3):258–264. doi:10.3802/jgo.2013.24.3.258.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.